Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

While Novo Nordisk has established a strong position in metabolic disease with the GLP-1 agonist semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for obesity, the pharmaceutical ...

rendering these products less effective or ineffective for conditions such as type 2 diabetes, cardiovascular disease, and chronic weight management. Novo Nordisk also noted 44 documented adverse ...